Google
ASND — ASCENDIS PHARMA AS (Healthcare >> Biotechnology)
ASND FAQ
What is ASND's P/E ratio?
ASCENDIS PHARMA AS (ASND) currently trades at a P/E ratio of 20.32.
What is ASND's ROE?
ASCENDIS PHARMA AS reports a Return on Equity (ROE) of 103.71%.
What is ASND's dividend yield?
ASCENDIS PHARMA AS offers a dividend yield of 0.00%.
What is ASND's Deepscope Quality Score?
Deepscope rates ASND's overall financial quality at 46 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy ASND?
Deepscope's AI Timing Score for ASND is 26 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does ASND belong to?
ASCENDIS PHARMA AS is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 210.45
Price
-8.39
(-3.83%)
Day Change
|
|
|---|
ASND, the overall quality is not good ( Quality = 46) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
Acceleration of ROE growth rate is below our criteria.
Negative growth of ROE in the last year.
ROE is decreasing significantly
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is ok , ...
| Quality Factors |
|
48% |
| In Recommendations? | In "Invest - GROWTH" Section |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 84 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 210.45 |
| PBV / Sector |
26.62 / 4.63
|
| Earning Per Share | 8.20 |
| PE / Sector |
20.32 / 17.43
|
| PEG or PE/Growth / Sector |
-0.71 / 0.53
|
| Average 1M Daily Value |
122.93 M
GREAT
|
| Average 1W Daily Value |
108.73 M
GREAT
|
| Timing Factors |
|
28% |
| Financial Health |
|
37% |
| Ability to Make Profit |
|
60% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-06-06 09:08:27 |
| Symbol | ASND |
| Name | ASCENDIS PHARMA AS |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 61.78 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 13,001.55 / 8,857.28 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: Tuborg Boulevard 12, Hellerup, Denmark, 2900
Phone: 45 70 22 22 44
Website: https://ascendispharma.com
Employees: 1,189
Sector: Healthcare >> Biotechnology
Description: Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
